Novo Nordisk's experimental obesity drug CagriSema shows blood pressure benefits

Novo Nordisk said on Thursday its experimental obesity drug CagriSema significantly reduced blood pressure in a late-stage trial, as the Danish drugmaker seeks to demonstrate health benefits beyond we... ...